Illumina Shares Outstanding 2006-2021 | ILMN

Illumina shares outstanding history from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Illumina shares outstanding for the quarter ending June 30, 2021 were 0.147B, a 0.68% decline year-over-year.
  • Illumina 2020 shares outstanding were 0.148B, a 0.67% decline from 2019.
  • Illumina 2019 shares outstanding were 0.149B, a 0% decline from 2018.
  • Illumina 2018 shares outstanding were 0.149B, a 0.68% increase from 2017.
Illumina Annual Shares Outstanding
(Millions of Shares)
2020 148
2019 149
2018 149
2017 148
2016 148
2015 149
2014 149
2013 140
2012 134
2011 139
2010 143
2009 137
2008 134
2007 108
2006 98
2005 80
Illumina Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 147
2021-03-31 147
2020-12-31 148
2020-09-30 148
2020-06-30 148
2020-03-31 148
2019-12-31 149
2019-09-30 148
2019-06-30 149
2019-03-31 149
2018-12-31 149
2018-09-30 149
2018-06-30 148
2018-03-31 148
2017-12-31 148
2017-09-30 148
2017-06-30 147
2017-03-31 147
2016-12-31 148
2016-09-30 148
2016-06-30 148
2016-03-31 148
2015-12-31 149
2015-09-30 150
2015-06-30 149
2015-03-31 149
2014-12-31 149
2014-09-30 148
2014-06-30 149
2014-03-31 151
2013-12-31 140
2013-09-30 141
2013-06-30 139
2013-03-31 124
2012-12-31 134
2012-09-30 133
2012-06-30 133
2012-03-31 134
2011-12-31 139
2011-09-30 136
2011-06-30 142
2011-03-31 153
2010-12-31 143
2010-09-30 145
2010-06-30 141
2010-03-31 136
2009-12-31 137
2009-09-30 140
2009-06-30 139
2009-03-31 133
2008-12-31 134
2008-09-30 120
2008-06-30 133
2008-03-31 128
2007-12-31 108
2007-09-30 119
2007-06-30 116
2007-03-31 107
2006-12-31 98
2006-09-30 101
2006-06-30 95
2006-03-31 83
2005-12-31 80
2005-09-30 82
2005-06-30 80
2005-03-31 77
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $62.433B $3.239B
Illumina, Inc. is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Their products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29